Dopamine D₃ Receptors Expressed by All Mesencephalic Dopamine Neurons

Jorge Diaz,¹ Catherine Pilon,² Bernard Le Foll,² Claude Gros,² Antoine Triller,³ Jean-Charles Schwartz,² and Pierre Sokoloff²

¹Laboratoire de Physiologie, Université René Descartes, 75006 Paris, France, ²Unité de Neurobiologie et Pharmacologie Moléculaire (Institut National de la Santé et de la Recherche Médicale U 109), Centre Paul Broca, 75014 Paris, France, and ³Biologie Cellulaire de la Synapse Normale et Pathologique (Institut National de la Santé et de la Recherche Médicale U 497), Ecole Normale Supérieure, 75230 Paris, France

A polyclonal antibody was generated using synthetic peptides designed in a specific sequence of the rat D₃ receptor (D₃R). Using transfected cells expressing recombinant D₃R, but not D₂ receptor, this antibody labeled 45–80 kDa species in Western blot analysis, immunoprecipitated a soluble fraction of [¹²⁵I]iodosulpride binding, and generated immunofluorescence, mainly in the cytoplasmic perinuclear region of the cells. In rat brain, the distribution of immunoreactivity matched that of D₃R binding, revealed using [¹²⁵I]R(+)-*trans*-7-hydroxy-2-[*N*-propyl-*N*-(3'-iodo-2'-propenyl)amino] tetralin ([¹²⁵I]7-*trans*-OH-PIPAT), with dense signals in the islands of Calleja and mammillary bodies, and moderate to low signals in the shell of nucleus accumbens (AccSh), frontoparietal cortex, substantia nigra (SN), ventral tegmental area (VTA) and lobules 9 and 10 of the cerebellum. Very low or no signals could be detected in other rat brain regions, including dorsal striatum, or in D₃R-deficient mouse brain. La-

beling of perikarya of AccSh and SN/VTA appeared with a characteristic punctuate distribution, mostly at the plasma membrane where it was not associated with synaptic boutons, as revealed by synaptophysin immunoreactivity. In SN/VTA, D₃R immunoreactivity was found on afferent terminals, arising from AccSh, in which destruction of intrinsic neurons by kainate infusions produced a loss of D₃R binding in both AccSh and SN/VTA. D₃R-immunoreactivity was also found in all tyrosine hydroxylase (TH)-positive neurons observed in SN, VTA and A8 retrorubral fields, where it could represent D₃ autoreceptors controlling dopamine neuron activities, in agreement with the elevated dopamine extracellular levels in projection areas of these neurons found in D₃R-deficient mice.

Key words: nucleus accumbens shell; substantia nigra; ventral tegmental area; D₃ receptor-deficient mice; tyrosine hydroxylase; synaptophysin

Converging pharmacological, genetic and human postmortem studies have implicated the D₃ receptor (D₃R) in the physiopathology and treatment of schizophrenia, drug addiction and depression (Pilla et al., 1999; Lammers et al., 2000; Schwartz et al., 2000). In rat brain, the largest D₃R expression densities occur in granule cells of the islands of Calleja and in medium-sized spiny neurons of the rostral and ventromedial shell of nucleus accumbens (AccSh), which coexpress the D₁ receptor and neuropeptides (Diaz et al., 1994; Diaz et al., 1995; Le Moine and Bloch, 1996). The neurons from AccSh receive their dopaminergic innervation from the ventral tegmental area (VTA) and other innervations from cerebral cortex, hippocampus and amygdala (Zahm and Brog, 1992; Penartz et al., 1994), project indirectly to entorhinal and prefrontal cortex and subserve the control of emotion, motivation and reward (Willner and Sheel-Krüger, 1991).

One aspect of the localization and function of the D₃R that is still highly debated is its occurrence as an autoreceptor, regulating the activity of dopamine neurons. We originally proposed the existence of D₃ autoreceptors on the basis of the expression in substantia nigra (SN) and VTA of D₃R mRNA, which strongly decreases after lesion of dopamine neurons (Sokoloff et al., 1990). This lesion, however, also downregulates postsynaptic D₃R in AccSh (Lévesque et al., 1995), by deprivation of brain-derived

neurotrophic factor (BDNF), an anterograde factor of dopamine neurons (Guillin et al., 1999). Hence the lesion-induced decrease in SN/VTA could reflect a similar process occurring in non-dopaminergic neurons.

Dopamine release (Tang et al., 1994) and synthesis (O'Hara et al., 1996) are inhibited by stimulation of the D₃R expressed in a transfected mesencephalic cell line and various agonists, with limited preference for the D₃R (Sautel et al., 1995), inhibits dopamine release, synthesis and neuron electrical activity (for review, see Levant, 1997), giving support to the existence of D₃ autoreceptors. However, the selectivity of these agonists toward the D₃R *in vivo* is strongly questioned, because they elicit similar inhibition of dopamine neuron activities in wild-type and D₃R-deficient mice (Koeltzow et al., 1998). In addition, dopamine autoreceptor functions are suppressed in D₂ receptor-deficient mice (Mercuri et al., 1997; L'hirondel et al., 1998). Nevertheless, dopamine extracellular levels in the nucleus accumbens (Koeltzow et al., 1998) and striatum (R. Gainetdinov and M. G. Caron, personal communication) are twice as high in D₃R-deficient as in wild-type mice, suggesting a control of dopamine neurons activity by the D₃R.

Direct confirmation of the role of the D₃R as an autoreceptor requires the demonstration of its occurrence in dopamine neurons, namely by using immunocytochemical methods. In fact, the antibodies directed against the D₃R reported so far generated immunolabeling that did not overlap distributions of D₃R mRNA and binding sites (Ariano and Sibley, 1994; Larson and Ariano, 1995; Khan et al., 1998), which questions their specificity. In the present study, we have generated a polyclonal antibody against the D₃R using sequence-specific peptides and assessed its specificity using recombinant receptors and D₃R-deficient mice and by comparison with D₃R binding. This antibody has then been used to examine cellular localizations of the D₃R by comparison with tyrosine hydroxylase (TH) and synaptophysin immunoreactivities.

Received June 23, 2000; revised Aug. 29, 2000; accepted Aug. 30, 2000.

This work was supported by a grant from the European Commission (FP5 Programme QL4-CT-1999-00075).

Correspondence should be addressed to Dr. Pierre Sokoloff, Unité de Neurobiologie et Pharmacologie Moléculaire (Institut National de la Santé et de la Recherche Médicale U 109), Centre Paul Broca, 2ter, rue d'Alésia, 75014 Paris, France. E-mail: sokol@broca.inserm.fr.

Copyright © 2000 Society for Neuroscience 0270-6474/00/208677-08\$15.00/0

MATERIALS AND METHODS

Immunization, antiserum titration and antibody purification. The immunization procedure conformed with local guidelines and has been performed by a person accredited by the French Minister of Agriculture (decree 87848). The peptide H-YGAGMSPVERTRNSL-OH (Y15L) was coupled by copolymerization with diazotized benzidine to bovine serum albumin (BSA) and subcutaneously injected together with complete Freund's adjuvant once, and then with the incomplete Freund's adjuvant each week for 4 weeks (268 μ g of peptide per injection), into female New Zealand rabbits. A booster injection in complete Freund's adjuvant was performed one month later with the same immunogen. The peptide Y15L was coupled to keyhole Limpet hemocyanin and used for a booster injection (500 μ g of the peptide) 3 months later. Three months later, the rabbits were injected with the peptide H-GAGMSPVERTRNSLY-OH (G15Y) coupled by copolymerization via bisdiazobenzidine to ovalbumin. Five booster injections with the latter peptide (350 μ g of peptide/injection) were made during the 3 years that followed. Rabbits were bled every 1–4 weeks and serum titer was assayed using [¹²⁵I]tyrosyl-labeled G15Y or Y15L and polyethyleneglycol precipitation.

The best titer antiserum collected at the end of the immunization procedure was precipitated with ammonium sulfate, filtered on DEAE-Sephadex and immunopurified on a HiTrap column (Amersham Pharmacia Biotech, Little Chalfont, UK) coupled to peptide G15Y by the amino group. The purified antibody was eluted in glycine-HCl 0.1 M, pH 2.3.

Western blot analysis. Wild-type and transfected Chinese hamster ovary (CHO) cells expressing the D₂ receptor or D₃R (Sokoloff et al., 1990) were scraped, harvested in 50 mM sodium phosphate buffer (PB) containing 150 mM NaCl (PBS), and homogenized in Tris-HCl buffer, 10 mM containing 5 mM EDTA and protease inhibitors (aprotinin, 1 μ g/ml; leupeptin, 1 μ g/ml; pepstatin, 0.1 μ g/ml). Membranes were isolated by centrifugation at 5000 $\times$ g for 10 min and solubilized in PAGE-loading buffer (50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 10% glycerol, 2% SDS, protease inhibitors as above). Proteins (20 μ g) were separated by electrophoresis in 12% SDS-polyacrylamide gel and electrophoretically transferred to nitrocellulose filters. Blots were blocked in PBS Blotto (Pierce, New York, NY) with 1% bovine serum albumin at room temperature for 2 hr. The blots were then incubated with purified anti-D₃R antibody (1:2000) overnight at 4°C. After three 10 min washes in PBS containing 0.05% Tween 20, blots were incubated with a horseradish peroxidase-conjugated goat anti-rabbit γ -globulins antibody (1:10,000, Pierce) for 1 hr at room temperature and developed using the enhanced chemiluminescence procedure (Amersham Pharmacia Biotech).

Receptor immunoprecipitation. Membranes of CHO cells expressing the D₂ receptor or D₃R were solubilized in 1% digitonin, 1% sodium cholate, and 1 M NaCl in 50 mM sodium phosphate buffer, pH 7.4, for 30 min at 4°C, diluted twice in sodium phosphate buffer, and centrifuged for 30 min at 50,000 $\times$ g. Supernatants (100 μ l) diluted 10 times in sodium phosphate buffer were incubated in a final volume of 400 μ l with diluted preimmune serum or antiserum and [¹²⁵I]iodosulpride (0.1 nM, 2200 Ci/mmol) (Amersham) overnight at 4°C. Some incubations were performed with the antibody previously presaturated overnight with the peptide G15Y (1 μ g/ μ l), and some were performed in the presence of 1 μ M emonapride to measure nonspecific binding. Fifty microliters of a 50% (v/v) suspension of protein A-Sepharose (Amersham Pharmacia Biotech) were added, and tubes were incubated under gentle agitation for 2 hr at 4°C and then centrifuged for 3 min at 14,000 rpm. Aliquots of supernatants were filtered through GF/B filters coated with 0.3% polyethylenimine, and filters were rinsed with 3 $\times$ 3 ml of cold sodium phosphate buffer. In preliminary experiments, this procedure allowed us to solubilize and recover up to 20% of membrane-bound receptors.

Animals, tissue, and cell preparation for immunohistochemistry and immunofluorescence. Male Wistar rats (180–250 gm, Iffa-Credo, L'Arbresles, France) or mice (see below) were anesthetized deeply with pentobarbital (30 mg/kg, i.p.) and then perfused transcardially with 50 ml of saline solution (0.9% NaCl warmed at 37°C), followed by 600 ml of an ice-cooled fixative solution containing 2% paraformaldehyde in 0.1 M PB, pH 7.5. The brains were removed, post-fixed in 2% paraformaldehyde for 1–2 hr at 4°C, and rinsed in PB solutions. Some brains were transferred into ascending series of sucrose solutions (10% overnight, 15% for 24 hr, and 20% for 24 hr), frozen and stored at –70°C, and then sectioned in coronal and sagittal planes with a cryostat in 30 μ m sections. Other brains were immediately cut in the same planes with a vibratome in 40 μ m sections that were collected, cryoprotected in PB containing 30% sucrose, and freeze-thawed (–75°C) to improve penetration of the antibodies. Cryostat or vibratome sections were collected in 0.05 M Tris buffer, pH 7.5, containing 150 mM NaCl (TBS) and then treated with blocking serum (5% normal donkey serum, 0.4% BSA, 0.1% gelatin, and 0.1% Tween 20 in TBS) for 1 hr at room temperature. CHO cells were cultured on 20 $\times$ 20 mm collagen-coated slides, rinsed with PBS, fixed for 30 min in 2% paraformaldehyde, rinsed again in 0.1 M glycine–PBS, and immersed in the blocking serum as above.

Detection of D₃R immunoreactivity by the immunoperoxidase method. The sections were incubated for 24–48 hr at room temperature with the immunopurified anti-D₃R receptor antibody diluted 1:2000 in TBS containing 5% normal donkey serum and 0.05% Tween 20 (TBS–NDST20). Some sections were incubated with the antibody previously presaturated overnight with the peptide G15Y (1 μ g/ μ l). The sections were rinsed (four

times for 10 min) in TBS containing 0.1% gelatin and 0.05% Tween 20 (TBS–GT20) and immersed for either 1–2 hr at room temperature or overnight at 4°C in biotinylated donkey anti-rabbit γ -globulins (Amersham) diluted 1:200 in TBS–NDST20. The sections were rinsed (three times for 10 min) in TBS–GT20 and then incubated for 1 hr at room temperature in avidin–biotin–HRP complex (ABC reagent, Vectastin-Elite; Vector Laboratories, Burlingame, CA). After rinsing in TBS containing Tween 20 (0.05%) and then in TBS, peroxidase activity was revealed by incubation with 3,3'-diaminobenzidine for 10–30 min at 4°C in the presence of hydrogen peroxide using the Sigma Fast diaminobenzidine tablets (Sigma, St. Louis, MO). The peroxidase reaction was stopped by several rinses in Tris-HCl. The sections were mounted on glass slides, dehydrated in graded ethanols, cleared, and then mounted in Acrytol for observation under a Zeiss Axiophot microscope.

Immunofluorescence experiments. Vibratome coronal sections taken at levels of both basal forebrain (nucleus accumbens–ventral pallidum) and midbrain (VTA–SN) regions were incubated for 24–48 hr at room temperature in a mixture of primary immunoreagents diluted in TBS–NDST20. The mixture consisted of purified anti-D₃R antibody diluted 1:2000 and mouse monoclonal antibodies directed against either synaptophysin (diluted 1:50) (Boehringer Mannheim Biochemica, Mannheim, Germany) or anti-TH (diluted 1:10,000) (Incstar, Stillwater, MN). Slides with fixed CHO cells were incubated for 48 hr at 4°C with the purified anti-D₃R antibody only, diluted 1:2,000. After four washes (10 min each) in TBS–GT20, the sections were incubated in FITC–donkey anti-mouse (Jackson ImmunoResearch, West Grove, PA) diluted 1:200 in TBS–NDST20, followed by Cy3–donkey anti-rabbit γ -globulins (Jackson ImmunoResearch), diluted 1:1000 in TBS–NDST20, for 1 hr at room temperature. To intensify the D₃R fluorescent immunostaining, some double-labeling experiments were performed using a biotinylated donkey anti-rabbit IgG (1:200 in TBS–NDST20) followed by three washes (10 min each) and incubation for 1 hr in Cy3–streptavidin (0.5 μ g/ml in TBS–T20). The sections were washed (three times for 10 min), mounted on Super Frost Plus slides, and then coverslipped using Vectashield mounting medium (Vector Laboratories) and nail polish to seal the coverslip. Sections were examined and photographed using Zeiss Plan-Neofluar objectives and band-pass filter sets for FITC and rhodamine. Control experiments were performed to ensure that each primary antibody did not react with the non-corresponding secondary antibody-conjugate. In such experiments, sections were incubated as follows: rabbit anti-D₃R antibody, followed by FITC–donkey anti-mouse or mouse anti-TH followed by Cy3–donkey anti-rabbit. In these controls, only light autofluorescence and no cross-reactive immunostaining were observed.

D₃R-deficient mice. Heterozygous mice bearing a mutation invalidating the D₃R gene, originally obtained from S. Fuchs (Weizmann Institute, Rehovot, Israel) (Accili et al., 1996), were bred and mated. DNA was prepared from a piece of the tail (3–5 mm) using the DNAeasy tissue kit (Qiagen France, Courtaboeuf, France) and amplified with the mixture of primers GCA GTG GTC ATG CCA GTT CAC TAT CAG and CCT GTT GTG TTG AAA CCA AAG AGG AGA GG, amplifying the exon 3 of the wild-type D₃R, and TGG ATG TGG AAT GTG TGC GAG and GAA ACC AAA GAG GAG AGG GCA GGA C, amplifying the PGK cassette of the mutated gene. Agarose gel electrophoresis allowed us to detect homozygous wild-type mice (a single band at 137 bp), homozygous mutated mice (a single band at 200 bp), and heterozygous mice (bands at 137 and 200 bp). Homozygous mutated mice and their wild-type littermates were used in the study.

Lesion studies. Male Sprague Dawley rats (180–200 gm, Iffa Credo, L'Arbresles) were anesthetized with pentobarbital (50 mg/kg). Nucleus accumbens lesions were made by infusion of kainate (1.5 μ l of a solution at 2.5 μ g/ml in 25 mM Tris-HCl buffer, pH 7.4, at the following coordinates: anterior-posterior +1.7 mm; lateral –1 mm; ventral –7 mm from the dorsal surface. The infusion cannula was left in position for 3 min after each one-side infusion. Animals were killed 10 d after stereotaxic surgery. Assessment of the placement and extent of the lesion was performed under microscopic observation of Nissl-stained sections.

Receptor autoradiography. Unfixed 10 μ m cryostat brain sections were preincubated at room temperature three times for 5 min in 50 mM sodium-HEPES buffer, pH 7.5, containing 1 mM EDTA and 0.1% BSA. They were incubated in the same buffer containing 0.2 nM [¹²⁵I]R(+)-trans-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino] tetralin ([¹²⁵I]trans-7-OH-PI-PAT; 2200 Ci/mmol; Amersham) for 45 min at room temperature. Nonspecific binding was determined by incubating adjacent sections in the same medium in the presence of 1 μ M dopamine. After incubation, slices were washed four times for 2 min in ice-cold sodium-HEPES buffer containing 100 mM NaCl, dipped in ice-cold distilled water, and then dried under a stream of cold air. Autoradiograms were generated by apposing sections to ³H-Hyperfilm (Amersham) for 2–4 d and developed in D-19 developer. Autoradiographic signals were quantified on two to three slices per animal using an image analyzer (IMSTAR, Paris, France). Gray values were converted to microcuries per gram wet weight using ¹²⁵I standard stripes (Amersham).

In situ hybridization. The procedure has been described previously (Diaz et al., 1995). Briefly, paraformaldehyde-fixed slices (10 μ m) were treated with proteinase K (1 μ g/ml) and then with 0.25% acetic anhydride in triethanolamine buffer. The sections were hybridized with a ³³P-radiolabeled cRNA probe for D₃R mRNA (2 $\times$ 10⁶ dpm per slide) in 65%

Figure 1. Generation of antibodies. *A*, Amino acid sequence alignments (single letter code) of dopamine D₂, D₃, and D₄ receptors and the peptides used in the study to generate antibodies. *B*, Generation of immunoreactivity against [¹²⁵I]-labeled peptides. A rabbit was immunized with peptides Y-15-L and G-15-Y injected at times indicated by arrows, and immunoreactivity in the serum was measured using [¹²⁵I]Y-15-L (○) or [¹²⁵I]G-15-Y (●). Immunoreactivity titer was the antiserum dilution giving 50% of maximal bound radioactivity (70–90% of total radioactivity in the assay), calculated from saturation curves established with four to six serial antiserum dilutions. Antisera were obtained from bleeding every 1–2 weeks.

deionized formamide, 10% dextran sulfate, 1× Denhardt's solution, 2× SSC, 0.1% sodium pyrophosphate, 100 μg/ml yeast tRNA, and 100 μg/ml denatured salmon sperm DNA. After incubation and rinsing, slices were treated with RNase A (200 μg/ml), washed and dehydrated through a graded series of ethanol, and apposed to films (Hyperfilm β-max, Amersham) for 1 month. Films were developed in D-19 developer (15°C) for 5 min, rinsed rapidly in deionized water, and fixed in 30% sodium thiosulfate for 10–20 min.

RESULTS

Generation of anti-D₃R antibodies

The immunizing peptide sequence was designed in the putative third intracytoplasmic loop of the rat D₃R, which has no homologies with the sequence of other dopamine receptor subtypes (Fig. 1*A*). A portion of this sequence has a strong homology with the human D₃R. A search in databases did not reveal any other homology with a known protein. A first peptide, Y15L, had an additional tyrosine residue at the N terminus, allowing coupling to the carrier tyrosines with diazotized benzidine, and was used to immunize rabbits. After the initial immunization and a booster injection, rabbits were subsequently boosted with a second peptide, G15Y, having the same sequence, but with the additional tyrosine used for coupling located at the C terminus instead of the N terminus. Immunoreactivity of the antisera was measured with the two peptides [¹²⁵I]-labeled at either the C or N terminus (Fig. 1*B*). Although immunoreactivity against [¹²⁵I]Y15L raised and reached a similar antiserum titer after each booster injection, immunoreactivity against [¹²⁵I]G15Y appeared only after G15Y injections, and its titer increased progressively thereafter. At the end of immunization, antisera titers were similar against the two iodinated peptides. Furthermore, antibodies had similar affinities for

Figure 2. The antibody recognizes the recombinant D₃R expressed in transfected cells. *A*, Western blot of crude membrane proteins of wild-type CHO cells (WT-CHO) or CHO cells expressing the D₃R (D3-CHO) or the D₂ receptor (D2-CHO) with the purified antibody without (–G15Y) or with (+G15Y) presaturation with the immunizing peptide G15Y. *B*, Immunoprecipitation of [¹²⁵I]iodosulpride binding sites solubilized from membranes of CHO cells expressing the D₃R (left) but not the D₂ receptor (right). Receptors solubilized and labeled with [¹²⁵I]iodosulpride were incubated in the presence of antiserum or preimmune serum in increasing dilutions, in the presence or absence of G-15-Y peptide. Receptor-antibody complexes were then precipitated with protein A-Sepharose beads, and the nonprecipitated receptors were assayed in the supernatant. *C*, D₃R immunofluorescence in wild-type CHO cells (left) or CHO cells expressing the D₃R (middle) or the D₂ receptor (right). Note the labeling at the plasma membrane of D₃R-expressing cells (arrow). No signal could be detected when the first antibody was omitted (data not shown).

Y15L and G15Y ($EC_{50} = 0.5$ nM; data not shown), as well as a shorter peptide S10L (see sequence on Fig. 1*A*), indicating that antibodies indeed recognized internal epitopes.

Characterization of antibodies using recombinant dopamine receptors

In crude membrane preparations of CHO cells expressing the D₃R that were subjected to SDS-PAGE, the immunopurified antibody labeled major bands at ~45 and ~80 kDa (Fig. 2*A*). Minor bands, possibly corresponding to degraded proteins, were also visible at ~60 kDa and below 35 kDa. All of these bands were absent when the antibody was presaturated with the immunizing peptide G15Y. No signal could be detected with membranes from wild-type or D₂ receptor-expressing CHO cells.

D₃ or D₂ receptors expressed by CHO cell lines were solubilized with a digitonin–cholate mixture and labeled with [¹²⁵I]iodosulpride in the presence of antiserum or preimmune serum. The activity in the supernatant was measured after precipitation of antibody–receptor complexes with immobilized protein A. As shown in Figure 2*B*, the antiserum immunoprecipitated >60% of solubilized D₃R, but not D₂ receptor, and the effect was abolished by presaturation of the antibody with the immunizing peptide. Because the antiserum had no effect on [¹²⁵I]iodosulpride binding without protein A (<5% inhibition at any dilution starting from 10^{-3} ; data not shown), the depletion of [¹²⁵I]iodosulpride binding in the supernatant of protein A precipitation represented true immunoprecipitation.

Strong immunofluorescence signals generated with an immunopurified antibody were detected on D₃R-expressing CHO cells, but not on wild-type nor D₂ receptor-expressing CHO cells (Fig. 2*C*). Most of the signal appeared in the cytoplasm of D₃R-expressing cells, particularly in the perinuclear region, but some cells also displayed immunofluorescence at the plasma membrane (Fig. 2*C*, arrow). No signal could be detected when the D₃R antibody was

omitted or presaturated with the immunizing peptide (data not shown).

Distribution of D₃ receptor immunoreactivity in rat and wild-type or D₃ receptor-deficient mouse brains

In rat brain slices, there was a close overlap between the distributions of D₃R immunoreactivity, revealed by immunoperoxidase, and binding sites for [¹²⁵I]trans-7-OH-PIPAT, a D₃R-selective ligand (Burris et al., 1994). Thus, highest immunoreactivity levels were found in the islands of Calleja (Fig. 3B), which also express the highest density of D₃R mRNA (Bouthenet et al., 1991; Diaz et al., 1995). Strong labeling was also observed in AccSh. A much weaker signal was observed in the core of nucleus accumbens (Fig. 3B), a region where D₃R mRNA and binding levels are weak (Fig. 3A) (Bouthenet et al., 1991; Diaz et al., 1995). In normal D₃R^{+/+} mouse brain, the D₃R immunolabeling was similar to that found in rat brain and undetectable in D₃R-deficient mouse brain (Fig. 3D,E).

A semiquantitative comparison between D₃R immunoreactivity, binding, and mRNA levels in rat brain (Table 1) shows an overall agreement between distributions of the three markers. For instance, a high level of D₃R immunoreactivity was found in mammillary bodies, a region expressing high levels of D₃R binding and mRNA (Bouthenet et al., 1991), whereas a much weaker signal was observed in dorsolateral striatum, where the latter markers are hardly detectable. Moderate signals were observed in the frontoparietal cortex, ventral pallidum, anteroventral thalamic nucleus, and lateral habenula, which also express D₃R binding (Table 1), whereas other brain regions contained very low or undetectable levels of both D₃R immunoreactivity and binding. The only discrepancy was found in the cerebellum, where high levels of D₃R binding and mRNA are present in lobules 9 and 10 (Bouthenet et al., 1991; Diaz et al., 1995), whereas weaker D₃R immunoreactivity was observed (Table 1). This suggested that the D₃R may differ in cerebellum and other brain regions, but cDNAs amplified from mRNAs extracted from cerebellar lobules 9 and 10 and from nucleus accumbens had identical sequences, notably in the region corresponding to the immunizing peptide (data not shown).

D₃ receptor immunoreactivity in the mesencephalon

Moderate D₃R immunoreactivity, revealed by the immunoperoxidase method, was found in the rat SN/VTA complex, where individual cell bodies were clearly visualized in all parts of the complex (Fig. 3H,J). Enlargement shows labeling of individual cell bodies in the SN pars compacta (Fig. 3J). The immunoreactivity was abolished by presaturation of the antibody with the immunizing peptide G15Y (Fig. 3I,K). In contrast, [¹²⁵I]trans-7-OH-PIPAT binding was prominent in a restricted part of the complex, at the junction between SN pars compacta and VTA (Fig. 3F), and did not overlap the highest D₃R mRNA densities (Fig. 3G). [¹²⁵I]trans-7-OH-PIPAT binding in this area indeed labeled the D₃R, because this binding was completely absent in D₃R-deficient mice (Fig. 4A,B). D₃R immunoreactivity, revealed by the immunoperoxidase method in SN/VTA, was largely absent in D₃R-deficient mice (Fig. 4C,D), and the characteristic punctuate distribution of D₃R immunofluorescence in neurons of VTA was completely absent in these mice (Fig. 4E,F). In addition, D₃R immunoreactivity, binding, and mRNA were present in the A8 retrorubral dopamine cell group in the rat (Table 1).

To investigate the possibility that a fraction of D₃R binding in SN/VTA was present on afferent fibers from extrinsic neurons, we performed lesions of neurons intrinsic to AccSh by local infusions of kainate. Ten days later, this lesion elicited disappearance of Nissl-stained cells centered in the shell part of nucleus accumbens, but extended to the core part of nucleus accumbens and medioventral striatum (data not shown). No signs of trans-synaptic degeneration were observed: intrinsic neurons present in SN/VTA were apparently normal in number and shape (data not shown). The lesion elicited large and identical decreases (−62 and −63%, respectively) in D₃R binding in both the lesioned area and ipsilateral SN/VTA (Fig. 5A,B).

Figure 3. Comparisons of D₃R binding (A, F), D₃R immunoreactivity (B–E, H–K), and D₃R mRNA (G) in brain slices of rat (A–C, F–K), D₃R^{+/+} (D), or D₃R^{−/−} (E) mice. D₃R binding sites were labeled with the selective D₃R radioligand [¹²⁵I]7-trans-OH-PIPAT, and immunoreactivity was revealed using diaminobenzidine and D₃R mRNA by *in situ* hybridization with a [³³P]-labeled riboprobe. In C, I, and K, the antibody was presaturated with the peptide G15Y. A–E show micrographs taken at the level of the ventral part of the striatal complex and F–K at the level of SN and VTA. In ventral striatum, [¹²⁵I]7-OH-PIPAT binding (A) and D₃R immunoreactivity (B) overlap; D₃R immunoreactivity was absent in D₃R^{−/−} mice (E). In SN/VTA, [¹²⁵I]7-OH-PIPAT binding (F) was prominent at the junction between SN pars compacta (SNc) and VTA, whereas D₃R mRNA (G) was enriched in the lateral part of SN (SNI) and present in cells of the SN pars reticulata (SNr), SNc, and VTA. D₃R immunoreactivity (H) was present in cells and fibers of SNI, SNc, SNr, and VTA. J and K are enlargements of the rectangles in H and I, respectively, showing individual labeled cell bodies in the SNc in J, ac, anterior commissure; Co, nucleus accumbens core; ICj, islands of Calleja; ICjM, island of Calleja major; lv, lateral ventricle; Sh, nucleus accumbens shell. Scale bars: A–C, F–I, 0.5 mm; D, E, 0.1 mm; J, K, 125 μ m.

Comparison of D₃ receptor and tyrosine hydroxylase immunofluorescences

To assess the occurrence of D₃ autoreceptors, double-labeling experiments with antibodies directed against the D₃R and TH were

Table 1. Compared distributions of D₃ receptor mRNA, binding, and immunoreactivity in rat brain structures

Brain region	D ₃ R mRNA ^a	D ₃ R binding ^b	D ₃ R-IR ^c
Frontoparietal cortex	+	+/++	++
Frontal cortex	+/-	+	+
Nucleus accumbens shell	++	++	++
Nucleus accumbens core	+	+	+
Islands of Calleja			
Granule cells	+++	++	++
Hilar region	+/-	+++	+++
Ventromedial striatum	+	+	+
Ventrolateral septum	+/-	+	+
Dorsal striatum	0	+/-	+/-
Ventral pallidum	+	++	++
Medial mammillary bodies	+++	+++	+++
Lateral mammillary bodies	0	0	0
Lateral hypothalamus	0	+	+
Anteroventral thalamic nucleus	+	++	++
Lateral habenula	+/-	++	++
Hippocampus	+/-	+/-	+/-
Ventral tegmental area	+/-	+	+
Substantia nigra pars reticulata	+/-	+/-	+
Substantia nigra pars compacta	+/-	++	+
Substantia nigra pars lateralis	+	+/-	+/-
A8 retrorubral field	+	+	+
Cerebellum (lobules 9 and 10)			
Purkinje cells	+++	+/-	+
Molecular layer	0	+++	++

^aData from Bouthenet et al. (1991) and Diaz et al. (1995).^bData obtained with [³H]7-OH-DPAT from Diaz et al. (1995) or with [¹²⁵I]trans-7-OH-PIPAT (present study).^cD₃R immunoreactivity. **Figure 4.** D₃R binding (*A, B*), immunoperoxidase (*C, D*), and immunofluorescence (*E, F*) in SN/VTA of D₃R^{+/+} (*A, C, E*) and D₃R^{-/-} (*B, D, F*) mice. *E* and *F* show photomicrographs taken in the VTA. Note that the punctate immunoreactivity is absent in D₃R^{-/-} mice. SNc, SN pars compacta; SNl, SN pars lateralis; SNr, SN pars reticulata. Scale bars: *A, B*, 0.2 mm; *C, D*, 100 μ m; *E, F*, 10 μ m. **Figure 5.** Loss of D₃R binding in both AccSh and VTA/SN 10 d after an infusion of kainate into the left nucleus accumbens. Sections in *A* show [¹²⁵I]7-OH-PIPAT binding at the level of the nucleus accumbens (*top*) and mesencephalon (*bottom*). *B*, Sections similar to those shown in *A* and obtained from four animals were analyzed by densitometry. **p* < 0.03 by the two-tailed Mann–Whitney *U* test.

performed on sections containing SN/VTA or AccSh, a region of dopamine neurons projection where the D₃R is abundant. In SN/VTA, D₃R immunofluorescence corresponded to the immunoreactivity revealed with the immunoperoxidase method (Figs. 3*H*, 6*A*). At lower magnification (Fig. 6*A, B*), distributions of D₃R and TH immunofluorescences were overlapping in the SN pars compacta and VTA but not in SN pars reticulata and SN pars lateralis, where most D₃R-positive cells were TH negative. Microscopic examination of every section from 10 animals (15–20 sections per animal) at high magnifications (see representative examples in Fig. 6*C–F*) indicated that all TH-positive cells also displayed D₃R immunofluorescence; we could not find any TH-positive cell not expressing D₃R immunofluorescence in SN and VTA. In contrast, some D₃R-positive cells (a few of them are designated by arrows in Fig. 6*D*) did not display TH immunofluorescence. At the highest magnification used (Fig. 6*E, F*), there were clearly distinct cellular localizations of the two immunofluorescences: D₃R immunofluorescence appeared with a characteristic punctuate distribution at the plasma cell membrane and within the cytoplasm, whereas TH immunofluorescence was homogeneously distributed in the cytoplasm. Both immunofluorescences were absent from the cell nucleus. In addition, on a limited number of sections (*n* = 3) taken at the level of the retrorubral A8 dopamine cell group, we also observed that all TH-positive cells also displayed D₃R immunofluorescence (data not shown).

In AccSh, D₃R immunofluorescence also appeared with a punctuate distribution at the plasma membrane of cell bodies and within the neuropil (Fig. 6*G*). TH immunofluorescence was mainly distinct from D₃ receptor immunofluorescence, with very rare apparent coincidences (Fig. 6*H*).

Comparison of D₃ receptor and synaptophysin immunofluorescences

To assess whether the D₃R immunofluorescence was localized at the vicinity of synaptic components, we compared distributions of D₃R and synaptophysin immunofluorescences in AccSh (Fig. 6*I*), islands of Calleja (Fig. 6*J*), and VTA (Fig. 6*K*). The punctuate distribution of D₃R immunofluorescence both in the cell bodies, mostly near the plasma membrane, and in the neuropil in the three regions did not correspond to the distribution of synaptophysin immunofluorescence, and only few apparent coincidences could be found.

DISCUSSION

Many studies have used antibodies raised against carrier-coupled synthetic peptides, the sequence of which is chosen in unique and predicted antigenic regions of the target protein. The antibodies raised in this manner are likely to recognize mainly the free, not the coupled, extremity of the peptide, which is a valuable strategy

Figure 6. Comparison of D₃R and TH and synaptophysin immunofluorescences in rat brain. *A, C, E, and G* show D₃R immunofluorescence alone (Cy3, red). *B, D, F, and H* show double-labeling immunofluorescence of D₃R (Cy3, red) and TH (FITC, green). *A* and *B* show pictures obtained in the whole SN/VTA complex. *C* and *D* show pictures taken at the level of the junction between SNc and VTA. Neurons expressing D₃R but not TH immunofluorescence are marked by arrows. *E* and *F* show neurons in the VTA. *G* and *H* are taken at the level of the nucleus accumbens. *I–K* show double labeling immunofluorescence of D₃R (Cy3, red) and synaptophysin (FITC, green). *I, J, and K* show photomicrographs taken at the level of the nucleus accumbens shell, islands of Calleja, and VTA, respectively. In the three regions, D₃R immunofluorescence has a punctuate distribution at the plasma cell membrane, which segregates in cellular components distinct from those containing synaptophysin. *SNc*, SN pars compacta; *SNl*, SN pars lateralis; *SNr*, SN pars reticulata. Scale bars: *A, B*, 1 mm; *C, D*, 125 μ m; *E, F*, 25 μ m; *G, H*, 10 μ m; *I–K*, 15 μ m.

if the chosen sequence is at the N or C termini of the target protein, but a possible drawback if the sequence is internal. In the case of the D₃R, the N-terminal sequence has several putative sites for N-glycosylation, which may hinder recognition of the native protein, and the C terminus displays significant homologies with D₂ and D₄ receptor corresponding sequences. Hence, we decided to generate antibodies by using a synthetic peptide taken at the level of the third intracytoplasmic loop, coupled to the carrier by its N terminus, and then using a peptide having the same sequence but

coupled by its C terminus. As expected, this strategy indeed favored generation of antibodies recognizing internal epitopes, because these antibodies display similar titer and affinity for the immunizing peptides, whether they are [¹²⁵I]tyrosyl-labeled at the C or N terminus. The immunopurified antibody also binds to denatured as well as native recombinant D₃R expressed by transfected CHO cells. The major immunoreactive species are ~40 and 80 kDa in size, and the smallest species may correspond to a degraded, incompletely synthesized, or nonglycosylated form (*M_r* 45,500 Da deduced from the predicted amino acid sequence), whereas the largest species may correspond to either SDS and reduction-resistant dimers or glycosylated forms. The species at ~80 kDa have the same apparent size as D₂/D₃ receptor binding sites labeled with photoaffinity radioligands using brain tissue homogenates (Amlaiky and Caron, 1985; Redouane et al., 1985), suggesting the largest as the active form. This hypothesis needs confirmation, however, because we could not reliably measure the apparent size of the native D₃R from rat brain, which is not surprising given its very low expression level: 10–100 times lower than that of the D₂ receptor (Lévesque et al., 1992).

Thus, in transfected CHO cells, the overexpressed D₃R recognized by the antibody is largely present as immature or degraded protein, which is in agreement with its main occurrence in the cytoplasm, particularly in the perinuclear region of the cell. This cellular localization markedly contrasts with that found in neurons, where the D₃R is apparently mainly present at the plasma membrane, with only few occurrences as cytoplasmic patches, probably associated with recycling or synthesizing vesicles. In addition, the antibody recognizes recombinant solubilized D₃R, in an active form able to bind a radioligand and precipitable by immobilized protein A. This antibody would therefore be a valuable tool for studying the D₃R regulation, e.g., phosphorylation.

In rat brain sections, the pattern of immunolabeling matched that of D₃R binding and transcripts, with highest levels present in the islands of Calleja and mammillary bodies, moderate to low levels in AccSh, frontoparietal cortex, lobules 9 and 10 in cerebellum, and SN/VTA, and very low levels in other brain structures including striatum. The observation that immunolabeling and D₃R binding patterns overlap is a strong criterion for assessing the specificity of this antibody, which was apparently not fulfilled in previous studies. In the latter, the specificity of the antibodies used was questionable because highest levels of alleged D₃R-like immunoreactivity were not found in AccSh or islands of Calleja but in striatum and core of nucleus accumbens (Ariano and Sibley, 1994) or in hippocampus (Khan et al., 1998), which contains low or undetectable levels of D₃R binding or mRNA. The selectivity of the antibody developed herein is also based on the solid evidence, lacking in previous studies, that the immunolabeling it generates is absent in D₃R-deficient mice. This antibody therefore appears to have the specificity required for reliable immunocytochemistry.

The only minor discrepancy identified so far is the lowest level of immunolabeling in lobules 9 and 10 of the cerebellum, as compared with D₃R binding and mRNA. Because we have presently confirmed that the D₃R in the cerebellum has a sequence identical to that found in the nucleus accumbens, this apparent mismatch could be because of an inappropriate tissue preparation, leading to a loss of accessibility of the antibody or antigenicity in this particular brain area. D₃R binding is present in dendritic trees of Purkinje cells of the cerebellar molecular layer (Diaz et al., 1995), which may not be totally preserved by the fixatives. Alternatively, the D₃R in the cerebellum could partly be in a form not recognized by the antibody. The sequence of the immunizing peptide contains a putative site for casein kinase 2 (S/T-X-X-D/E), a protein kinase very abundant in brain (Blanquet, 2000). Phosphorylation by this or a similar enzyme activity at this site may hinder recognition by the antibody.

The antibody developed in the present study allowed us to not only confirm the localization of the D₃R in rat brain but also to address the important issue of its occurrence as an autoreceptor. Three distinct kinds of immunolabeling localization were found in

SN/NTA that most likely correspond to the D₃R, because the immunolabeling herein is absent in D₃R-deficient mice. The first is expressed by non-dopaminergic neurons, which are the most abundant in the SN pars lateralis and also contain the highest levels of D₃R mRNA. This suggests that a large fraction of D₃R gene transcripts are expressed by non-dopaminergic neurons, which may be liable to downregulation of D₃R expression after dopamine neuron denervation by 6-hydroxydopamine (Sokoloff et al., 1990), similar to that occurring in the nucleus accumbens (Lévesque et al., 1995) as a result of BDNF deprivation (Guillin et al., 1999). It remains to be determined whether the putative downregulation of D₃R expression in non-dopaminergic mesencephalic neurons after dopamine neuron ablation also results from the loss of BDNF, as is the case of striatal neurons (Guillin et al., 1999), or from the loss of another factor. BDNF and its receptor *trkB* are expressed in mesencephalon (Altar et al., 1994; Seroogy et al., 1994), together with other neurotrophic factors (Fallon and Loughlin, 1995).

The second localization of D₃R immunolabeling in SN/NTA most likely corresponds to presynaptic heteroreceptors present on terminals of neurons originating from AccSh. Such a pathway has been identified by tract-tracing experiments (Berendse et al., 1992). In agreement, we found that a lesion by kainate of accumbal neurons decreased D₃R binding to a similar extent in AccSh and SN/NTA. This indicates that the D₃R in this latter area is mainly present on afferent terminals.

In SN, NTA, and the A8 retrorubral field, we found a third localization of D₃R immunoreactivity in all dopamine neurons observed, which were identified as TH-positive neurons. This observation is at variance with our previous double *in situ* hybridization studies (Diaz et al., 1995), which allowed us to detect only a few neurons expressing both tyrosine hydroxylase and D₃R mRNAs. In fact, long exposure of photographic emulsion after *in situ* hybridization with a D₃R mRNA probe produced weak but distinct signals evenly distributed within cells of SN/NTA (J. Diaz, unpublished results), in agreement with the occurrence of D₃ autoreceptors in all dopamine neurons and the higher sensitivity of double immunofluorescence compared with double *in situ* hybridization.

In dopamine neurons, as in postsynaptic neurons in AccSh, D₃R immunoreactivity appears distinct from cytoplasmic TH immunoreactivity, with a striking punctuate distribution along the plasma membrane, not overlapping synaptophysin immunoreactivity. The D₃R therefore appears not to be present in the vicinity of synaptic boutons, and very rare apparent co-occurrences of D₃R and TH immunoreactivities were noticed in fibers of both SN/NTA and AccSh. This result suggests that the D₃R is mainly extrasynaptic, like the D₁ and D₂ receptors (Yung et al., 1995), and that dopamine acts through the D₃R at some distance of its releasing sites, i.e., in a paracrine manner suggested previously (Diaz et al., 1995). This situation is not exceptional for neuromodulators, because other examples exist, e.g., for serotonin (Bunin and Wightman, 1999) or neurotensin (Boudin et al., 1998). Insofar as the sensitivities of immunofluorescence detection at nerve terminals and perikarya are identical, the results also imply that D₃ autoreceptors are rather somatodendritic, but confirmation of this localization requires the use of higher resolution methods.

In agreement with the selective somatodendritic localization of D₃ autoreceptors, the inhibitory control of dopamine release by nerve terminals seems to be exerted exclusively by D₂ autoreceptors (L'hirondel et al., 1998). D₃ autoreceptors, together with D₂ autoreceptors (Mercuri et al., 1997), may thus rather control the electrical activity of dopamine neurons, which would explain the elevated extracellular dopamine in projection areas of these neurons in D₃R-deficient mice. This control could have been masked in experiments using compounds inadequately selective of the D₃R (Koeltzow et al., 1998), because the compounds used also activate the D₂ receptor. Alternatively, D₃ autoreceptors could not be operant in anesthetized animals or *in vitro* in brain slices used in electrophysiological studies (Mercuri et al., 1997; Koeltzow et al., 1998), whereas elevated dopamine extracellular levels were mea-

sured in freely moving D₃R-deficient mice. Finally, D₃ autoreceptors may mediate yet unrecognized control of other dopamine neuron activities, such as synthesis or release of neuropeptides coexpressed with dopamine in these neurons, e.g., neurotensin, cholecystokinin, or neurotrophins.

REFERENCES

- Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park B-H, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S (1996) A targeted mutation of the D₃ receptor gene is associated with hyperactivity in mice. *Proc Natl Acad Sci USA* 93:1945–1949.
- Altar CA, Siuciak JA, Wright P, Ip NY, Lindsay RM, Wiegand SJ (1994) *In situ* hybridization of *trkB* and *trkC* receptor mRNA in rat forebrain and association with high-affinity binding of [¹²⁵I] BDNF, [¹²⁵I] NGF-4/5 and [¹²⁵I] NT-3. *Eur J Neurosci* 6:1389–1405.
- Amlaiki N, Caron MG (1985) Photoaffinity labeling of the D₂-dopamine receptor using a novel high affinity radioiodinated probe. *J Biol Chem* 260:1983–1986.
- Ariano MA, Sibley DR (1994) Dopamine receptor distribution in the rat CNS: elucidation using anti-peptide antisera directed against the D_{1A} and D₃ subtypes. *Brain Res* 649:95–110.
- Berendse HW, Groenewegen HJ, Lohman AHM (1992) Compartmental distribution of ventral striatal neurons projecting to the mesencephalon in the rat. *J Neurosci* 12:2079–2103.
- Blanquet PR (2000) Casein kinase 2 as a potentially important enzyme in the nervous system. *Prog Neurobiol* 60:211–246.
- Boudin H, Pélaprat D, Rostène W, Pickel VM, Beaudet A (1998) Correlative ultrastructural distribution of neurotensin receptor proteins and binding sites in the rat substantia nigra. *J Neurosci* 18:8473–8484.
- Bouthenet M-L, Souil E, Martres M-P, Sokoloff P, Giros B, Schwartz J-C (1991) Localization of dopamine D₃ receptor mRNA in the rat brain using *in situ* hybridization histochemistry: comparison with D₂ receptor mRNA. *Brain Res* 564:203–219.
- Bunin MA, Wightman RM (1999) Paracrine neurotransmission in the CNS: involvement of 5-HT. *Trends Neurosci* 22:377–382.
- Burris KD, Filtz TM, Chumpradit S, Kung MP, Foulon C, Hensler JG, Kung HF, Molinoff PB (1994) Characterization of [¹²⁵I](R)-*trans*-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino] tetralin binding to dopamine D₃ receptors in rat olfactory tubercle. *J Pharmacol Exp Ther* 268:935–942.
- Diaz J, Lévesque D, Griffon N, Lammers CH, Martres M-P, Sokoloff P, Schwartz J-C (1994) Opposing roles for dopamine D₂ and D₃ receptors on neurotensin mRNA expression in nucleus accumbens. *Eur J Neurosci* 6:1384–1387.
- Diaz J, Lévesque D, Lammers CH, Griffon N, Martres M-P, Schwartz J-C, Sokoloff P (1995) Phenotypical characterization of neurons expressing the dopamine D₃ receptor. *Neuroscience* 65:731–745.
- Fallon JH, Loughlin SE (1995) Substantia nigra. In: *The rat nervous system* (Paxinos G, ed), pp 215–237. San Diego: Academic.
- Guillin O, Damier L, Griffon N, Diaz J, Carroll P, Schwartz J-C, Sokoloff P (1999) Role of brain-derived neurotrophic factor in the control of D₃ receptor expression. *Eur J Neuropsychopharmacol* 9:S184–S185.
- Khan ZU, Gutierrez A, Martin R, Penafiel A, Rivera A, De La Calle A (1998) Differential regional and cellular distribution of dopamine D₂-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. *J Comp Neurol* 402:353–371.
- Koeltzow TE, Xu M, Cooper DC, Hu XT, Tonggawa S, Wolf ME, White FJ (1998) Alterations in dopamine release but not dopamine autoreceptor function in dopamine D₃ receptor mutant mice. *J Neurosci* 18:2231–2238.
- Lammers CH, Diaz J, Schwartz J-C, Sokoloff P (2000) Selective increase of dopamine D₃ receptor gene expression as a common effect of chronic antidepressant treatments. *Mol Psychiatry* 5:378–388.
- Larson ER, Ariano MA (1995) D₃ and D₂ dopamine receptors: visualization of cellular expression patterns in motor and limbic structures. *Synapse* 20:325–337.
- Le Moine C, Bloch B (1996) Expression of the D₃ dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D₁ and D₂ dopamine receptors. *Neuroscience* 73:131–143.
- Levant B (1997) The D₃ dopamine receptor: neurobiology and potential clinical relevance. *Pharmacol Rev* 49:231–252.
- Lévesque D, Diaz J, Pilon C, Martres M-P, Giros B, Souil E, Schott D, Morgat J-L, Schwartz J-C, Sokoloff P (1992) Identification, characterization and localization of the dopamine D₃ receptor in rat brain using 7-[³H]-hydroxy-N,N di-n-propyl-2-aminotetralin. *Proc Natl Acad Sci USA* 89:8155–8159.
- Lévesque D, Martres M-P, Diaz J, Griffon N, Lammers CH, Sokoloff P, Schwartz J-C (1995) A paradoxical regulation of the dopamine D₃ receptor expression suggests the involvement of an anterograde factor from dopamine neurons. *Proc Natl Acad Sci USA* 92:1719–1723.
- L'hirondel M, Chéramy A, Gedeheu G, Artaud F, Saiardi A, Borrelli E, Glowinski J (1998) Lack of autoreceptor-mediated inhibitory control of

- dopamine release in striatal synaptosomes of D₂ receptor-deficient mice. *Brain Res* 792:253–262.
- Mercuri NB, Daiardi A, Bonci A, Picetti R, Calabresi P, Bernardi G, Borrelli E (1997) Loss of autoreceptor function in dopaminergic neurons form dopamine D₂ receptor-deficient mice. *Neuroscience* 79:323–327.
- O'Hara CM, Uhland-Smith A, O'Malley KL, Todd RD (1996) Inhibition of dopamine synthesis by dopamine D₂ and D₃ but not D₄ receptors. *J Pharmacol Exp Ther* 277:186–192.
- Pennartz CM, Groenewegen HJ, Lopes da Silva FH (1994) The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. *Prog Neurobiol* 42:719–761.
- Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz J-C, Everitt BJ, Sokoloff P (1999) Selective inhibition of cocaine-seeking behaviour by a partial dopamine D₃ receptor agonist. *Nature* 400:371–375.
- Redouane K, Sokoloff P, Schwartz J-C, Hamdi P, Mann A, Wermuth CG, Roy J, Morgat J-L (1985) Photoaffinity labeling of D₂ dopamine binding subunits from rat striatum, anterior pituitary and olfactory bulb with a new probe, [³H]azidosulpride. *Biochem Biophys Res Commun* 130:1086–1092.
- Sautel F, Griffon N, Lévesque D, Pilon C, Schwartz JC, Sokoloff P (1995) A functional test identifies dopamine agonists selective for D₃ versus D₂ receptors. *NeuroReport* 6:329–332.
- Schwartz J-C, Diaz J, Pilon C, Sokoloff P (2000) Possible implications of the D₃ receptor in schizophrenia and antipsychotic drug actions. *Brain Res Rev* 31:277–287.
- Seroogy KB, KH L, Tran TMD, Guthrie KM, Isackson PJ, Gall CM (1994) Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. *J Comp Neurol* 342:321–334.
- Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C (1990) Molecular cloning and characterization of a novel dopamine receptor (D₃) as a target for neuroleptics. *Nature* 347:146–151.
- Tang L, Todd RD, O'Malley KL (1994) Dopamine D₂ and D₃ receptors inhibit dopamine release. *J Pharmacol Exp Ther* 270:475–479.
- Willner P, Sheel-Krüger J (1991) The mesolimbic dopamine system: from motivation to action. Chichester: Wiley.
- Yung KKL, Bolam JP, Smith AD, Hersch SM, Ciliax BJ, Levey AI (1995) Immunocytochemical localization of D₁ and D₂ dopamine receptors in the basal ganglia of the rat: light and electron microscopy. *Neuroscience* 65:709–730.
- Zahm DS, Brog JS (1992) On the significance of subterritories in the "accumbens" part of the rat ventral striatum. *Neuroscience* 50:751–767.